- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02082483
Coronary Artery Disease Screening in Kidney Transplant Candidates (CADScreening)
Pilot Study to Determine Feasibility of a Randomized Trial of Screening for Coronary Artery Disease in Kidney Transplant Candidates
Kidney transplant candidates are at very high risk for coronary artery disease (CAD). The optimal strategy to monitor and maintain the cardiac fitness of patients awaiting kidney transplantation is unknown. Currently patients undergo annual testing; however, screening for CAD may increase morbidity and mortality by:
- exposing patients to the risk of angiography and revascularization procedures
- delaying or excluding patients from life saving transplantation.
Before proceeding with a definitive study to determine whether screening is necessary, feasibility will be determined in this pilot study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This pilot trial will determine the feasibility of a multi-center, randomized, parallel group definitive trial. Asymptomatic wait-listed patients will be randomized to routine screening for coronary artery disease (CAD) (i.e. Myocardial Perfusion Scintigraphy (MPS) or Dobutamine Stress Echo (DSE)) as per the current standard of care versus selective screening based on symptoms. Patients enrolled in the pilot will be included in the definitive trial analysis. The pilot trial will include four Canadian centres. The definitive trial will aim to determine if a strategy of selective use of screening tests (i.e. Myocardial Perfusion Scintigraphy or Dobutamine Stress Echo) only in the presence of symptoms (i.e. chest pain, dyspnea etc) is non-inferior with respect to the composite endpoint of non-fatal MI and cardiac death compared to screening all asymptomatic wait-listed patients at regular intervals as described in transplant specific guidelines published by the National Kidney Foundation.
Currently there is no strong evidence for or against using routine cardiac screening of asymptomatic transplant patients, more evidence based randomized clinical trials are needed. This need is further highlighted by a number of factors such as: wait-listed patients are increasing in number and medical complexity; longer wait times and changing donor characteristics can increase CAD risk; wait-listed patients are at high risk for CAD but are commonly asymptomatic; the standard of care is not evidence based and is expensive; the current standard may be harmful. The study will determine feasibility of a definitive trial through the measures outlined under 'Outcome Measures'.
End stage renal disease (ESRD) patients wait-listed for kidney transplantation will be randomized to undergo selective screening for CAD, in which patients are only screened if they develop symptoms suggestive of CAD or the current standard of care that involves regular screening for CAD at fixed time intervals based on the presence of risk factors. Patients will remain on the pilot trial protocol until death, non-fatal MI, transplantation, permanent removal from the waiting list for any reason, or 24 months after enrolment in the pilot trial. During wait-listing, follow-up telephone interviews and chart reviews will be performed every six months. After transplantation, an in-person follow up visit and chart review will occur at the time of discharge from hospital, and a telephone interview and chart review will be performed 3 months after transplantation. Patients will be followed for 24 months from the date of enrolment. Patients who receive a kidney transplant during the study will be followed for 27 months.
For the pilot trial, descriptive analyses are planned. Feasibility will be summarized with proportions, rates, means, and medians as appropriate. Comparison of the definitive trial outcomes between treatment groups, will not be done at the end of the internal pilot as these patients will be included in the definitive trial. Analyses of enrolment rates and consent rates will be done after the enrolment phase of the pilot trial in late 2014. An interim analysis of protocol adherence is planned in mid 2016 in support of the definitive trial funding application in September, 2016.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Vancouver General Hospital
-
Vancouver, British Columbia, Canada
- St. Paul's Hospital
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare Hamilton
-
Ottawa, Ontario, Canada
- The Ottawa Hospital
-
Toronto, Ontario, Canada
- University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada
- Royal Victoria Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age greater than 18 years
- active on the deceased donor transplant waiting list
Exclusion Criteria:
- patients not expected to require further screening for CAD prior to transplantation by the current standard of care. For example, a diabetic patient recently screened for CAD and expected to be transplanted <12 months from the start of the study would not require further screening according to current guidelines and would be ineligible
- patients with signs or symptoms suggestive of active cardiac disease such as unstable coronary syndromes, de-compensated heart failure, uncontrolled arrhythmia, and severe valvular heart disease
- patient who have been put "on hold" for transplantation due to a medical problem (e.g. an infection)
- prior extra-renal transplant recipients
- multi-organ transplant candidates (e.g. kidney pancreas transplant candidates)
- patients with a planned living donor transplant
- patients unable to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Selective Screening
Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography.
If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
|
Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography.
If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
|
No Intervention: Regular Screening
Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation).
If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Adhering to the Expected Number of Screening Tests
Time Frame: Up to 27 months
|
Adherence will be defined by completion of the expected number of screening tests during follow up as per the 2005 National Kidney Foundation guidelines.
For example, the expected number of screening tests in a diabetic patient who did not develop symptoms would be zero in the selective screening group, while the same patient would be expected to completed two screening tests if randomized to regular screening.
Tests performed for clinical symptoms of CAD will be excluded from the determination of adherence.
|
Up to 27 months
|
Enrolment Rates
Time Frame: Measured after enrolment period of 6 months
|
The total number of subjects enrolled across all sites will be monitored monthly from the CRO, Ottawa Hospital Research Institute (OHRI), which issues the randomization scheme.
|
Measured after enrolment period of 6 months
|
Consent Rate
Time Frame: Measured after enrolment period of 6 months
|
The percentage of patients willing to participate will be established at each site.
Willingness to enrol in the study will be recorded on each patient's case report form along with the reason for any refusal to consent.
|
Measured after enrolment period of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Cardiac Events
Time Frame: Up to 27 months
|
A composite outcome of cardiac death and non-fatal myocardial infarction will be looked at and adjudicated by a blinded clinical endpoints committee.
|
Up to 27 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Transplant Events
Time Frame: Up to 24 months
|
Patient transplantation will be documented on the subject case report form.
|
Up to 24 months
|
Number of Participants With Wait List Holds or Removals
Time Frame: Up to 24 months
|
Indication for hold or removal will be measured as well.
|
Up to 24 months
|
Number of Health Care Encounters
Time Frame: Up to 27 months
|
The information captured will include outpatient, day care, and emergency room use (including any diagnostic testing and all medical and surgical interventions (i.e.
use of thrombolytics, revascularization procedures), inpatient encounters and resource utilization (hospitalizations, procedural costs), physician consultations.
Indirect patients costs (time off work, transportation costs), and quality of life (measured using the short-form 36 (SF36).
|
Up to 27 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John Gill, MD, St. Paul's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H14-00141
- MOP 133509 (Other Grant/Funding Number: Canadian Institutes of Health Research)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Selective Screening
-
Federal State Budget Institution Research Center...Recruiting
-
Centers for Disease Control and PreventionCompleted
-
Vastra Gotaland RegionRecruiting
-
Belkin Laser Ltd.Queen's University, Belfast; Moorfields Eye Hospital NHS Foundation Trust; Universita... and other collaboratorsCompletedOcular Hypertension | Open Angle GlaucomaIsrael, United Kingdom, Italy
-
University of FloridaPatient-Centered Outcomes Research InstituteEnrolling by invitation
-
Peking University People's HospitalSun Yat-sen University; Fudan University; Sun Yat-Sen Memorial Hospital of Sun... and other collaboratorsCompletedBreast Cancer | Bone MetastasesChina
-
National Institute of Allergy and Infectious Diseases...Ohio Department of Health, City of Cincinnati Board of HealthCompleted
-
University of La LagunaCompletedHepatitis C Virus InfectionSpain
-
University of British ColumbiaUniversity of SydneyRecruitingCardiovascular Diseases | End Stage Renal Disease | Kidney Transplantation | Dialysis Related ComplicationCanada, United States, United Kingdom, Germany
-
Eunice Kennedy Shriver National Institute of Child...Completed